CompletedNCT05248594

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Montefiore Medical Center
Principal Investigator: Jennifer Davila, MD
Children's Hospital at Montefiore
Intervention: HEMLIBRA(drug)
Enrollment: 71 enrolled
Eligibility: All sexes
Timeline: 2024 – 2025

Study locations (10)

Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center, Hartford, Connecticut, United States
Yale Hemophilia Treatment Center, New Haven, Connecticut, United States
Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States
Newark Beth Israel, Newark, New Jersey, United States
Western NY Blood Care - Research Foundation for SUNY, Buffalo, New York, United States
Comprehensive Center for Hemophilia and Coagulation Disorders (Cornell), New York, New York, United States
Mary M Gooley Hemophilia Center, Inc., Rochester, New York, United States
Northwell Health Hemostasis and Thrombosis Center, Staten Island, New York, United States
SUNY Upstate Hemophilia Treatment Center - HTC 058, Syracuse, New York, United States
Children's Hospital at Montefiore, The Bronx, New York, United States

Collaborators

Genentech, Inc. · Regional Comprehensive Hemophilia Treatment Center (Mount Sinai) · Massachusetts General Comprehensive Hemophilia and Thrombosis Treatment Center · Rutgers Robert Wood Johnson Medical School

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05248594 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials